Johns Hopkins Medicine researchers provided clinical validation supporting the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The clearance moves fungal diagnostics closer to more scalable bedside workflows, where faster identification can affect antifungal initiation timing. If adopted broadly, urine-based triage could reduce reliance on slower laboratory pathways, particularly in high-risk patients where diagnostic uncertainty can delay effective therapy.